August 16-17, 2023
Digital Conference8:00AM EDT // 1:00PM BST // 2:00PM CESTKey Sessions
Gerold Meinhardt
Panel Discussion: Overviewing the Current ADC Landscape: What Can we Expect from the Future of ADC Drug Development?
Daiichi Sankyo Inc., USA
Paul Moore
ADC Design: Enhancing Functionality through Integrated Components
Zymeworks, Canada
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Antibody Drug Conjugates - EST/EDT (Eastern Daylight, GMT-4)
keyboard_arrow_leftSearch & Filter
search
Topics
Antibody Drug Conjugates - EST/EDT (Eastern Daylight, GMT-4)
search
Topics
Showing 1 of 1 Streams
Antibody Drug Conjugates
08:00 - 08:05
Welcoming Remarks
- Lottie Leinfellner - Digital Events Conference Producer, Informa Connect, UK
08:05 - 08:35
An Overview of Daiichi Sankyo’s (DS) ADC Technology and Update on Clinical Development of DS ADC Pipeline
- Akiko Zembutsu - Senior Director, Daiichi Sankyo Co., Ltd. Japan
08:35 - 09:35
Panel Discussion: Overviewing the Current ADC Landscape: What Can we Expect from the Future of ADC Drug Development?
- Gerold Meinhardt - Vice President Asset & Portfolio Management, Daiichi Sankyo Inc., USA
- Sujiet Puthenveetil - Director, AstraZeneca, USA
- Pradeep Dhal - Senior R&D Director, Sanofi, USA
- Julian Andreev - Senior Fellow, Regeneron Pharmaceuticals, USA
- Guiseppe Curigliano - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Italy
- Changshou Gao - Senior Vice President & Chief Technology Officer, Innovent Biologics, USA
09:35 - 10:05
Approach to Designing Potentially Best-in-Class ADCs
- Ben Ayers - Vice President, Antibody-Drug Conjugates, Hummingbird Bioscience, Singapore
10:05 - 10:35
Coffee Break & Networking Opportunities on the ConnectMe Platform
10:35 - 11:05
Pivekimab Sunirine (IMGN632): A Next-Generation ADC for CD123+ Hematologic Malignancies
- Benjamin Oshrine - Medical Director, Immunogen, USA
11:05 - 11:35
ADC Design: Enhancing Functionality through Integrated Components
- Paul Moore - Chief Scientific Officer, Zymeworks, Canada
11:35 - 12:05
Linker Matters: Highly Stable and Efficient ADCs Made with Native Antibodies and Peptide Linkers
- Philipp Spycher - CEO & Co-Founder, Araris Biotech AG, Switzerland
12:05 - 12:35
Coffee Break & Networking Opportunities on the ConnectMe Platform
12:35 - 13:05
Novel ADC Linker for High Drug to Antibody Ratios and Rapid Payload Release for Improved Cytotoxic Effect (Final Talk Title TBC)
- Léo Marx - Medicinal Chemistry Project Manager, Debiopharm Research & Manufacturing, Switzerland
13:05 - 13:35
Antibody Drug Conjugates with Improved Therapeutic Indexes Driven by Optimal Conjugation Site
Filter
Topics